Dr. Mark H. Fleischman, MD
Mohs Surgery (MOHS-Micrographic Surgery Physician)
- Medicare participating
At a glance
- Medical school
- Creighton University School of Medicine (2000)
- Years since graduation
- 26
- In the NPI registry since
- 2006
- Medicare patients seen, 2024
- 1,578
The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is
Education and training
- 2000Medical school: Creighton University School of Medicine
- 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier
Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).
Specialties and state licenses
-
MOHS-Micrographic Surgery Physician primary
KS license 430545 · MO license 2004016900 -
Dermatology Physician
KS license 430545 · MO license 2004016900
As reported to the NPI registry. To confirm a license is current, check the state medical board.
Where they work
Medical groups
- Dermatology and Skin Cancer Specialists LLC (47 clinicians)
Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.
Medicare patients and services
- Medicare patients, 2024
- 1,578
- Services billed
- 13,604
- Patients’ average age
- 76
| Service | Times | Patients |
|---|---|---|
| Destruction of precancer skin growth, 2-14 growths | 4,726 | 749 |
| Established patient office or other outpatient visit, 20-29 minutes | 1,826 | 1,250 |
| Destruction of precancer skin growth, 1 growth | 1,480 | 960 |
| Biopsy of related skin growth, first growth | 950 | 704 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks | 513 | 368 |
| Biopsy of related skin growth, each additional growth | 378 | 216 |
| Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks | 255 | 167 |
| Complicated repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet, 2.6-7.5 cm | 237 | 202 |
| Destruction of skin growth, 1-14 growths | 190 | 168 |
| New patient office or other outpatient visit, 30-44 minutes | 161 | 161 |
Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.
Medicare prescriptions
Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.
Payments from drug and device companies
In 2025, 21 companies reported 71 payments worth $2,005 in total to this clinician.
| Food and Beverage | $1,996 |
|---|---|
| Education | $9.65 |
What the payments were for
| Company | What it was for | Amount |
|---|---|---|
| AbbVie Inc. Mar 21, 2025 | Education SKYRIZI · IMMUNOLOGY · in-kind | $9.65 |
Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.
From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.
Industry-funded research
Named as a principal investigator on 16 industry-funded studies in 2025, from 4 companies. The companies reported $512,168 in research payments for these studies, mostly to the institutions running them.
- A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
AbbVie Inc. · Active, not recruiting · NCT06468228 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy
AbbVie Inc. · Active, not recruiting · NCT05889182 - M20-465 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
AbbVie Inc. - Real-World Effectiveness of Dupilumab in Patients With Prurigo Nodularis: An Observational Study
Sanofi US Services Inc. · Completed · NCT05991323 - A Study to Assess Disease Activity and Safety of Lutikizumab in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa
AbbVie Inc. - M23-698 - A Study to Assess Change in Disease Activity and Adverse Events of Oral Upadacitinib in Adult and Adolescent Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy (St…
AbbVie Inc. - A Phase 3, Multi-center, Open-label, Single-arm Study to Assess the Safety of Apremilast (AMG 407) in Pediatric Participants From 6 Through 17 Years of Age With Mild to Moderate Plaque Psoriasis
Amgen Inc. - Observation priority e short - lebrikizumab - atopic dermatitis
Eli Lilly and Company - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)
AbbVie Inc. · Completed · NCT06333860 - A Study to Learn How Safe and Effective Risankizumab is When Compared to Deucravacitinib to Treat Participants With Moderate Plaque Psoriasis and Who Need to Try Systemic Treatment (Works Throughout the Whole Body)
AbbVie Inc.
From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.